Small molecule compounds that inhibit HDAC enzymatic activities are known as HDAC inhibitors (HDIs), which emerge as a promising class of drugs for a variety of conditions including cancer, immune diseases, metabolic disorders, and neurological diseases (Christensen et al., 2011; Falkenberg and Johnstone, 2014). This evidence concerns the gene HDAC9 and metabolic disease.